ANIX - Anixa to get additional US patent linked to breast cancer vaccine technology

• Anixa Biosciences ( NASDAQ: ANIX ) said the U.S. Patent and Trademark Office (USPTO) issued a Notice of Allowance for a new patent related to the company's breast cancer vaccine technology.
• The company said the technology has been exclusively licensed from and is being developed in partnership with Cleveland Clinic.
• The patent is titled 'Breast Cancer Vaccine' and the lead inventor is Vincent Tuohy of the Department of Inflammation and Immunity at Cleveland Clinic's Lerner Research Institute.
• "This breast cancer vaccine has the potential to prevent Triple Negative Breast Cancer ("TNBC"), the deadliest form of breast cancer, and perhaps other forms of breast cancer that express alpha-lactalbumin," said Anixa Chairman and CEO Amit Kumar.

For further details see: